fgf23 concentrations  (Cusabio)

Journal: JBMR Plus

Article Title: Effects of Primary Kidney Disease Etiology on Renal Osteodystrophy in Pediatric Dialysis Patients

doi: 10.1002/jbm4.10601

Figure Lengend Snippet: Biochemical Parameters According to Primary Kidney Disease

Article Snippet: FGF23 concentrations were determined using a C‐terminal FGF23 ELISA kit (Quidel, San Diego, CA, USA), which detects both full‐length, intact FGF23 and C‐terminal FGF23 fragments (reference mean ± standard deviation [SD], 73 ± 38 RU/mL). ( ) Bone biopsy samples were obtained from the anterior iliac crest biopsy (2 cm below the anterior superior iliac spine) using a modified Bordier trephine needle, and therapy with active vitamin D sterols was discontinued for 4 weeks before the procedure, as previously described. ( ) Double tetracycline‐labeling was given (10 mg/kg/d for 2 days, followed by a 10‐day tetracycline‐free period, then a subsequent relabeling with 10 mg/kg/d for 2 days; the biopsy was performed 2 to 4 days after the last dose).

Techniques:

Journal: JBMR Plus

Article Title: Effects of Primary Kidney Disease Etiology on Renal Osteodystrophy in Pediatric Dialysis Patients

doi: 10.1002/jbm4.10601

Figure Lengend Snippet: Spearman Correlation Coefficients for Bone Histomorphometric Parameters

Article Snippet: FGF23 concentrations were determined using a C‐terminal FGF23 ELISA kit (Quidel, San Diego, CA, USA), which detects both full‐length, intact FGF23 and C‐terminal FGF23 fragments (reference mean ± standard deviation [SD], 73 ± 38 RU/mL). ( ) Bone biopsy samples were obtained from the anterior iliac crest biopsy (2 cm below the anterior superior iliac spine) using a modified Bordier trephine needle, and therapy with active vitamin D sterols was discontinued for 4 weeks before the procedure, as previously described. ( ) Double tetracycline‐labeling was given (10 mg/kg/d for 2 days, followed by a 10‐day tetracycline‐free period, then a subsequent relabeling with 10 mg/kg/d for 2 days; the biopsy was performed 2 to 4 days after the last dose).

Techniques:

Journal: Journal of the American Geriatrics Society

Article Title: FGF23 and Cause-specific Mortality in Community-living Individuals – the Health, Aging, and Body Composition Study

doi: 10.1111/jgs.16910

Figure Lengend Snippet: Baseline Characteristics by Quartiles of FGF23 in Community-Living Older Adults

Article Snippet: Exposure The primary exposure was the plasma intact FGF23 concentration, measured using specimens thawed for the first time (Kainos Laboratories Tokyo, Japan).

Techniques:

Journal: Journal of the American Geriatrics Society

Article Title: FGF23 and Cause-specific Mortality in Community-living Individuals – the Health, Aging, and Body Composition Study

doi: 10.1111/jgs.16910

Figure Lengend Snippet: Associations of Intact FGF23 with Mortality and its Subtypes

Article Snippet: Exposure The primary exposure was the plasma intact FGF23 concentration, measured using specimens thawed for the first time (Kainos Laboratories Tokyo, Japan).

Techniques:

Journal: Journal of the American Geriatrics Society

Article Title: FGF23 and Cause-specific Mortality in Community-living Individuals – the Health, Aging, and Body Composition Study

doi: 10.1111/jgs.16910

Figure Lengend Snippet: Hazard ratios (HRs) represented per two-fold higher concentrations of FGF23. FGF23 concentrations presented after log transformation. Model is adjusted for age, gender, site, education, race, body mass index (BMI), history of myocardial infarction (MI), systolic blood pressure (SBP), prevalent diabetes and cardiovascular disease (CVD), hypertension (HTN) medications, smoking, albumin, C-reactive protein concentrations, statin use, total cholesterol, calcium, phosphate, PTH, estimated glomerular filtration pressure (eGFR) and urine albumin to creatinine ratio (UACR).

Article Snippet: Exposure The primary exposure was the plasma intact FGF23 concentration, measured using specimens thawed for the first time (Kainos Laboratories Tokyo, Japan).

Techniques: Transformation Assay, Medications, Filtration